The MOCS2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, in which the MOCS2 gene has been disrupted to eliminate functional expression of molybdopterin synthase sulfurase. This product provides a loss-of-function model in a human Burkitt lymphoma suspension cell background, enabling investigation of MOCS2-dependent molybdenum cofactor (MoCo) biosynthesis and its downstream metabolic consequences. The polyclonal nature of the knockout ensures that the population reflects a heterogeneous set of editing events, offering a robust system for studying pathway disruptions without clonal selection biases.
Raji cells are an Epstein-Barr virus (EBV)-immortalized B lymphocyte line isolated from a Burkitt lymphoma patient, characterized by their malignant phenotype, suspension growth, and retained antigen-presentation machinery. As a widely utilized hematological model, Raji cells facilitate studies of B cell biology, viral oncogenesis, and high-throughput pharmacological screening. Their rapid proliferation and adaptability to various culture formats make them particularly suitable for functional genomics approaches, including CRISPR-mediated gene disruption to interrogate metabolic and signaling networks in a lymphomagenic context.
MOCS2 encodes the small subunit of molybdopterin synthase, catalyzing the transfer of sulfur from MOCS3 to precursor Z to yield molybdopterin, the organic backbone of MoCo. This step is essential for MoCo biosynthesis, and MOCS2 functions downstream of MOCS1 and upstream of gephyrin (GPHN), which mediates MoCo insertion into apoenzymes. Key downstream targets include sulfite oxidase (SUOX), xanthine dehydrogenase (XDH), aldehyde oxidase (AOX1), and the mitochondrial amidoxime reducing components MARC1/2. Transcriptional regulation of MOCS2 involves factors such as SP1 and NF-Y, linking its expression to broader cellular homeostasis. Disruption of MOCS2 in Raji cells ablates MoCo production, inactivating SUOX and XDH, thereby impairing sulfite detoxification and purine catabolism, and triggering toxic sulfite accumulation and oxidative stress.
In the Raji B lymphocyte host, MOCS2 knockout creates a model of molybdenum cofactor deficiency type B, a severe neurometabolic disorder. Although Raji cells are not neuronal, the disruption of MoCo-dependent enzymes in this hematopoietic context allows dissection of cell-autonomous metabolic defects, oxidative stress responses, and potential compensatory mechanisms. The suspension growth of Raji cells further enables scalable experiments to assess sulfite-induced cytotoxicity, apoptotic signaling, and adaptation to mitochondrial dysfunction, offering insights into the molecular pathology underlying sulfite oxidase deficiency and related neurological conditions.
Researchers can employ this MOCS2 knockout polyclonal cell population to model molybdenum cofactor deficiency, perform sulfite oxidase dysfunction studies, and evaluate therapeutic strategies such as gene therapy vectors or pharmacological chaperones. Representative assays include RT-qPCR for MOCS2 transcript quantification, western blot analysis of MOCS2 protein levels, sulfite oxidase and xanthine dehydrogenase activity measurements, HPLC-based MoCo quantification, and viability or apoptosis assays under sulfite stress conditions. These applications support drug screening for MoCo deficiency, neurotoxicity research, and metabolic disorder investigations. For further information on application protocols and technical support, please contact Ascent Research.
